首页 > 最新文献

Revue medicale de Liege最新文献

英文 中文
[Ocular metallosis : when a tiny foreign body oxidises a whole eye !] 眼金属病:当一个微小的异物氧化整个眼睛!]
Pub Date : 2025-10-01
Pierre Lesoinne, Fabrice Korczewski

Ocular metallosis is a rare ophthalmologic condition characterized by alterations of all intraocular structures in the setting of a metallic intraocular foreign body. There are two main types: ocular siderosis - the most frequent and most deleterious - and ocular chalcosis. The lesions can lead to total functional loss of the affected eye. We report the case of a young man presenting a late-stage ocular siderosis, for whom surgical removal of the foreign body did not result in functional recovery, given the end-stage lesions. We then summarize the pathophysiological, diagnostic and therapeutic aspects of ocular metallosis. We particularly want to insist on the importance of a prevention policy in at-risk situations, and of quick management in case of a suspected metallic intraocular foreign body, in order to avoid ocular morbidity.

眼金属病是一种罕见的眼科疾病,其特征是在金属眼内异物的情况下改变所有眼内结构。主要有两种类型:最常见和最有害的眼铁沉着和眼黄疸。病变可导致受影响的眼睛完全丧失功能。我们报告的情况下,一个年轻的男子提出了一个晚期的眼铁沉着,为他手术切除异物没有导致功能恢复,鉴于终末期病变。然后我们总结了眼金属病的病理生理,诊断和治疗方面。我们特别要强调在危险情况下预防政策的重要性,以及在可疑金属眼内异物的情况下快速处理的重要性,以避免眼部发病率。
{"title":"[Ocular metallosis : when a tiny foreign body oxidises a whole eye !]","authors":"Pierre Lesoinne, Fabrice Korczewski","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ocular metallosis is a rare ophthalmologic condition characterized by alterations of all intraocular structures in the setting of a metallic intraocular foreign body. There are two main types: ocular siderosis - the most frequent and most deleterious - and ocular chalcosis. The lesions can lead to total functional loss of the affected eye. We report the case of a young man presenting a late-stage ocular siderosis, for whom surgical removal of the foreign body did not result in functional recovery, given the end-stage lesions. We then summarize the pathophysiological, diagnostic and therapeutic aspects of ocular metallosis. We particularly want to insist on the importance of a prevention policy in at-risk situations, and of quick management in case of a suspected metallic intraocular foreign body, in order to avoid ocular morbidity.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"645-649"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Ethmoidal metastasis of prostatic carcinoma]. [前列腺癌筛样转移]。
Pub Date : 2025-10-01
François Radermecker, Nancy Detrembleur, Mathilde Grégoire, Gilles Reuter, Louis Deprez, Florence Rogister

We report a rare case of ethmoidal metastasis from a prostatic carcinoma in an elderly patient. This metastasis was revealed solely by exophthalmos, with no associated nasal symptoms. Radiological and histopathological analyses confirmed the unusual diagnosis of a sinus metastasis from a prostatic adenocarcinoma. This case highlights the importance of a thorough diagnostic approach in the presence of an uncommon unilateral orbitopathy.

我们报告一例罕见的老年前列腺癌筛样转移病例。这种转移仅表现为眼球突出,没有相关的鼻症状。放射学和组织病理学分析证实了前列腺腺癌鼻窦转移的不寻常诊断。本病例强调了对罕见的单侧眼窝病变进行彻底诊断的重要性。
{"title":"[Ethmoidal metastasis of prostatic carcinoma].","authors":"François Radermecker, Nancy Detrembleur, Mathilde Grégoire, Gilles Reuter, Louis Deprez, Florence Rogister","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report a rare case of ethmoidal metastasis from a prostatic carcinoma in an elderly patient. This metastasis was revealed solely by exophthalmos, with no associated nasal symptoms. Radiological and histopathological analyses confirmed the unusual diagnosis of a sinus metastasis from a prostatic adenocarcinoma. This case highlights the importance of a thorough diagnostic approach in the presence of an uncommon unilateral orbitopathy.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"625-627"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[About the use of gadolinium-based contrast agents in patients with chronic kidney disease]. 【关于慢性肾脏疾病患者使用钆基造影剂】。
Pub Date : 2025-10-01
François Cousin, Martin Moïse, Cédric Ilbert, Paul Meunier, François Jouret

Gadolinium-based contrast agents (GBCA) are contrast agents used in magnetic resonance imaging (MRI). In patients with chronic kidney disease (CKD), their use has long been a source of concern due to the risk of nephrogenic systemic fibrosis. However, advances in the choice of GBCA have considerably improved their safety. Since 2017, the European Medicines Agency (EMA) has banned linear GBCA, except for a strict hepato-specific use, due to their instability and increased risk of tissue retention. Macrocyclic GBCA are much more stable and are now widely preferred. Their chemical structure enables stronger chelation of Gd3+, significantly reducing the risk of dissociation and accumulation in the body, even in patients with CKD. Recent studies have demonstrated Gd3+ accumulation in the basal ganglia after repeated administrations of linear GBCAs, even in patients with normal kidney function. To date, no clinical consequences have been demonstrated. After rigorous evaluation of the benefit-risk ratio of a GBCA injection and limitation of injected doses, MRI based on macrocyclic GBCA does not compromise the safety of patients with CKD.

钆基造影剂(GBCA)是用于磁共振成像(MRI)的造影剂。在慢性肾脏疾病(CKD)患者中,由于肾源性全身性纤维化的风险,它们的使用一直是一个令人担忧的问题。然而,在选择GBCA方面的进步已经大大提高了它们的安全性。自2017年以来,欧洲药品管理局(EMA)已禁止线性GBCA,除非严格用于肝脏特异性用途,因为它们不稳定且组织保留的风险增加。大环GBCA更稳定,现在被广泛使用。它们的化学结构使Gd3+的螯合作用更强,显著降低了体内游离和积累的风险,即使在CKD患者中也是如此。最近的研究表明,即使在肾功能正常的患者中,反复给予线性gbca后,基底神经节中也会出现Gd3+积累。到目前为止,还没有临床结果被证实。经过对注射GBCA的获益-风险比和注射剂量限制的严格评估,基于大环GBCA的MRI不会损害CKD患者的安全性。
{"title":"[About the use of gadolinium-based contrast agents in patients with chronic kidney disease].","authors":"François Cousin, Martin Moïse, Cédric Ilbert, Paul Meunier, François Jouret","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Gadolinium-based contrast agents (GBCA) are contrast agents used in magnetic resonance imaging (MRI). In patients with chronic kidney disease (CKD), their use has long been a source of concern due to the risk of nephrogenic systemic fibrosis. However, advances in the choice of GBCA have considerably improved their safety. Since 2017, the European Medicines Agency (EMA) has banned linear GBCA, except for a strict hepato-specific use, due to their instability and increased risk of tissue retention. Macrocyclic GBCA are much more stable and are now widely preferred. Their chemical structure enables stronger chelation of Gd3+, significantly reducing the risk of dissociation and accumulation in the body, even in patients with CKD. Recent studies have demonstrated Gd3+ accumulation in the basal ganglia after repeated administrations of linear GBCAs, even in patients with normal kidney function. To date, no clinical consequences have been demonstrated. After rigorous evaluation of the benefit-risk ratio of a GBCA injection and limitation of injected doses, MRI based on macrocyclic GBCA does not compromise the safety of patients with CKD.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"650-653"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Screening for sleep apnea-hypopnea syndrome : data from Liège University Hospital Center with a mandibular movement measurement device (Brizzy]. [筛选睡眠呼吸暂停-低通气综合征:数据来自li法兰西大学医院中心下颌运动测量装置(Brizzy)]。
Pub Date : 2025-09-01
Simon Peerboom, Celena Azouaoui, Valérie Quaedvlieg, Julien Fanielle, Olivier Bonhomme, Pierre Maquet, Renaud Louis

Obstructive sleep apnea-hypopnea syndrome (OSAHS) is an underrated and heavy public health problem. Polysomnography (PSG) remains GOLD-standard examination but we also use ambulatory screening tests including Brizzy, which measures mandibular movements. The aim is to report on our experience with the Brizzy and compare it with PSG data. Data from 812 patients clinically suspected of having OSAHS who underwent a Brizzy screening test prescribed at the University Hospital of Liège between 2012 and 2020 were collected and analyzed retrospectively. These data were compared with data from their subsequent PSG, when available. The characteristics of patients with a positive Brizzy test, i.e., a respiratory disturbance index (RDI) > 15 h-1, were those typically described, namely a majority of men over the age of 50 who were obese. Sixty-seven percent of the patients evaluated had an RDI > 15 h-1, and this index correlated with the apnea-hypopnea index (AHI) on PSG (R = 0.47, p < 0.0001). Only 26 % of patients with a positive Brizzy test underwent PSG within two years. A Brizzy IPR > 15 h-1 has a sensitivity of 97 % and a positive predictive value of 90 % for detecting an AHI > 15 h-1 on PSG. Thus, the IPR measured by mandibular movements using the Brizzy is an interesting tool for screening for OSAHS.

阻塞性睡眠呼吸暂停低通气综合征(OSAHS)是一个被低估的严重公共卫生问题。多导睡眠图(PSG)仍然是gold标准检查,但我们也使用动态筛查测试,包括测量下颌运动的Brizzy。目的是报告我们使用Brizzy的经验,并将其与PSG数据进行比较。收集2012年至2020年期间在利弗里奇大学医院接受Brizzy筛查试验的812名临床怀疑患有OSAHS的患者的数据并进行回顾性分析。将这些数据与随后获得的PSG数据进行比较。Brizzy试验阳性患者的特征,即呼吸障碍指数(RDI) bbb15 h-1,是典型的描述,即大多数50岁以上的男性肥胖。67%的患者RDI为bbb15 h-1,该指数与PSG上的呼吸暂停-低通气指数(AHI)相关(R = 0.47, p < 0.0001)。只有26%的Brizzy阳性患者在两年内接受了PSG检查。Brizzy IPR > 15 h-1在PSG上检测AHI > 15 h-1的灵敏度为97%,阳性预测值为90%。因此,使用Brizzy通过下颌运动测量IPR是一种筛查OSAHS的有趣工具。
{"title":"[Screening for sleep apnea-hypopnea syndrome : data from Liège University Hospital Center with a mandibular movement measurement device (Brizzy].","authors":"Simon Peerboom, Celena Azouaoui, Valérie Quaedvlieg, Julien Fanielle, Olivier Bonhomme, Pierre Maquet, Renaud Louis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Obstructive sleep apnea-hypopnea syndrome (OSAHS) is an underrated and heavy public health problem. Polysomnography (PSG) remains GOLD-standard examination but we also use ambulatory screening tests including Brizzy, which measures mandibular movements. The aim is to report on our experience with the Brizzy and compare it with PSG data. Data from 812 patients clinically suspected of having OSAHS who underwent a Brizzy screening test prescribed at the University Hospital of Liège between 2012 and 2020 were collected and analyzed retrospectively. These data were compared with data from their subsequent PSG, when available. The characteristics of patients with a positive Brizzy test, i.e., a respiratory disturbance index (RDI) > 15 h-1, were those typically described, namely a majority of men over the age of 50 who were obese. Sixty-seven percent of the patients evaluated had an RDI > 15 h-1, and this index correlated with the apnea-hypopnea index (AHI) on PSG (R = 0.47, p < 0.0001). Only 26 % of patients with a positive Brizzy test underwent PSG within two years. A Brizzy IPR > 15 h-1 has a sensitivity of 97 % and a positive predictive value of 90 % for detecting an AHI > 15 h-1 on PSG. Thus, the IPR measured by mandibular movements using the Brizzy is an interesting tool for screening for OSAHS.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"606-611"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Impact of the «ELADEB» tool and a case manager for hospitalized patients with complex care]. [«ELADEB»工具和病例管理器对复杂护理住院患者的影响]。
Pub Date : 2025-09-01
Gilles Henrard, Jean-Luc Belche, Isabelle Heymans, Nathalie Maes, Joy Josseaux, Éric Adam

Patients with complex care needs present numerous challenges: the care they receive is often associated with more hospital admissions. The care provided to this group could benefit from being more goal-oriented and better integrated. However, strengthening a net-work of care for these patients starting from hospitalization remains a challenge. This is particularly due to the fact that available assessment tools poorly reflect patient overall needs, especially psychosocial ones, and do not help identify their priorities.Therefore, we implemented a care strategy that includes the use of the ELADEB tool combined with the intervention of a case manager. We present the results of a retrospective study using administrative data from 109 hospitalized patients. We measured the effect of this intervention by comparing the number and duration of hospitalizations, as well as the number of readmissions within 30 days of discharge, one year before the intervention and one year after. We observed a statistically significant decrease in unplanned hospitalizations, average lengths of stay, and readmissions in the year following the intervention. These exploratory results highlight the potential value of such an intervention, yet a rigorous prospective evaluation in our context remains to be done.

有复杂护理需求的患者面临着许多挑战:他们接受的护理往往与更多的住院次数有关。向这一群体提供的护理可以从更加以目标为导向和更好地整合中受益。然而,从住院开始加强对这些患者的护理网络仍然是一项挑战。这主要是由于现有的评估工具不能很好地反映患者的总体需求,特别是心理社会需求,并且不能帮助确定他们的优先事项。因此,我们实施了一项护理策略,其中包括使用ELADEB工具并结合病例管理员的干预。我们报告了一项回顾性研究的结果,该研究使用了109名住院患者的行政数据。我们通过比较住院的次数和持续时间,以及出院后30天内再入院的次数,干预前一年和干预后一年,来衡量这种干预的效果。我们观察到,在干预后的一年中,计划外住院、平均住院时间和再入院的发生率有统计学上的显著下降。这些探索性结果突出了这种干预的潜在价值,但在我们的背景下,严格的前瞻性评估仍有待完成。
{"title":"[Impact of the «ELADEB» tool and a case manager for hospitalized patients with complex care].","authors":"Gilles Henrard, Jean-Luc Belche, Isabelle Heymans, Nathalie Maes, Joy Josseaux, Éric Adam","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Patients with complex care needs present numerous challenges: the care they receive is often associated with more hospital admissions. The care provided to this group could benefit from being more goal-oriented and better integrated. However, strengthening a net-work of care for these patients starting from hospitalization remains a challenge. This is particularly due to the fact that available assessment tools poorly reflect patient overall needs, especially psychosocial ones, and do not help identify their priorities.Therefore, we implemented a care strategy that includes the use of the ELADEB tool combined with the intervention of a case manager. We present the results of a retrospective study using administrative data from 109 hospitalized patients. We measured the effect of this intervention by comparing the number and duration of hospitalizations, as well as the number of readmissions within 30 days of discharge, one year before the intervention and one year after. We observed a statistically significant decrease in unplanned hospitalizations, average lengths of stay, and readmissions in the year following the intervention. These exploratory results highlight the potential value of such an intervention, yet a rigorous prospective evaluation in our context remains to be done.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"584-591"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Plea for an early diagnosis of people at risk of developing symptomatic type 1 diabetes]. [呼吁对有患1型糖尿病症状风险的人进行早期诊断]。
Pub Date : 2025-09-01
André Scheen, Madeleine Wera, Jean-Christophe Philips, Julie Fudvoye, Marie-Christine Lebrethon, Nicolas Paquot

Type 1 diabetes (T1D) is an autoimmune chronic disease that leads to the destruction of pancreatic beta cells and thus requires lifelong insulin therapy. Constraints and adverse events associated to insulin therapy are well known as well as the risk of long-term complications linked to chronic hyperglycaemia. Symptomatic T1D is preceded by a preclinical asymptomatic period, which is characterized by the presence of at least two auto-antibodies against beta cell without disturbances of blood glucose control (stage 1) or, in addition to immunological biomarkers, by the presence of mild dysglycaemia reflecting a defect of early insulin secretion (stage 2). Recent objectives for the management of this disease are to detect people with auto-antibodies in order to propose an early specific management to delay the shift to clinical stage (stage 3) and to limit its severity as well. The screening concerns as first step relatives of patients living with T1D and individuals presenting other auto-immune diseases, but may be extended to the general population (especially in young people) with the improvement of techniques of auto-antibody assays. Teplizumab, an anti-CD3 monoclonal antibody, slows down the decline of insulin secretion by beta cells, both in people at stage 2 and early stage 3. This medication, which may be considered as a disease-modifying agent of T1D, was approved in November 2022 by the U.S. Food and Drug Administration (FDA) and is currently evaluated by the European Medicines Agency (EMA).

1型糖尿病(T1D)是一种自身免疫性慢性疾病,导致胰腺细胞的破坏,因此需要终身胰岛素治疗。众所周知,与胰岛素治疗相关的限制和不良事件以及与慢性高血糖相关的长期并发症的风险。有症状的T1D之前有一个临床前无症状期,其特征是存在至少两种针对β细胞的自身抗体,没有血糖控制紊乱(1期),或者,除了免疫生物标志物外,存在反映早期胰岛素分泌缺陷的轻度血糖异常(2期)。该疾病最近的治疗目标是检测患者的自身抗体,以便提出早期特异性治疗方案,以延缓转入临床阶段(3期),并限制其严重程度。筛查首先关注的是T1D患者的亲属和出现其他自身免疫性疾病的个体,但随着自身抗体检测技术的改进,可能会扩展到一般人群(特别是年轻人)。Teplizumab是一种抗cd3单克隆抗体,可减缓2期和3期早期患者β细胞胰岛素分泌的下降。该药物可能被认为是T1D的疾病调节剂,于2022年11月获得美国食品和药物管理局(FDA)的批准,目前正在接受欧洲药品管理局(EMA)的评估。
{"title":"[Plea for an early diagnosis of people at risk of developing symptomatic type 1 diabetes].","authors":"André Scheen, Madeleine Wera, Jean-Christophe Philips, Julie Fudvoye, Marie-Christine Lebrethon, Nicolas Paquot","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is an autoimmune chronic disease that leads to the destruction of pancreatic beta cells and thus requires lifelong insulin therapy. Constraints and adverse events associated to insulin therapy are well known as well as the risk of long-term complications linked to chronic hyperglycaemia. Symptomatic T1D is preceded by a preclinical asymptomatic period, which is characterized by the presence of at least two auto-antibodies against beta cell without disturbances of blood glucose control (stage 1) or, in addition to immunological biomarkers, by the presence of mild dysglycaemia reflecting a defect of early insulin secretion (stage 2). Recent objectives for the management of this disease are to detect people with auto-antibodies in order to propose an early specific management to delay the shift to clinical stage (stage 3) and to limit its severity as well. The screening concerns as first step relatives of patients living with T1D and individuals presenting other auto-immune diseases, but may be extended to the general population (especially in young people) with the improvement of techniques of auto-antibody assays. Teplizumab, an anti-CD3 monoclonal antibody, slows down the decline of insulin secretion by beta cells, both in people at stage 2 and early stage 3. This medication, which may be considered as a disease-modifying agent of T1D, was approved in November 2022 by the U.S. Food and Drug Administration (FDA) and is currently evaluated by the European Medicines Agency (EMA).</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"598-605"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Traumatic pulmonary pseudocyst]. [创伤性肺假性囊肿]。
Pub Date : 2025-09-01
Arnaud Lempereur, Michèle Yerna, Ali Deeba

Traumatic pulmonary pseudocysts (TPPs) are rare but clinically relevant complications of thoracic trauma, often misdiagnosed due to their non-specific presentation and resemblance to other cavitary pulmonary lesions. We report the case of a 26-year-old male presenting with delayed symptoms following a fall, ultimately diagnosed with multiple TPPs via thoracic CT scan. The patient experienced a favourable evolution with conservative management, including aerosolized tranexamic acid for minor hemoptysis. This case highlights the importance of thorough clinical history-taking and imaging in establishing the diagnosis, avoiding unnecessary antibiotic therapy, and limiting hospitalization. TPPs generally resolve spontaneously, but complications such as infection or hemorrhage may require intervention. Early recognition and tailored management are essential to optimize outcomes.

创伤性肺假性囊肿(TPPs)是一种罕见但与临床相关的胸外伤并发症,由于其非特异性表现和与其他空腔性肺病变相似,经常被误诊。我们报告一例26岁男性患者,在跌倒后出现延迟症状,最终通过胸部CT扫描诊断为多发TPPs。患者在保守治疗下进展良好,包括雾化氨甲环酸治疗轻微咯血。本病例强调了全面的临床病史和影像学检查在确定诊断、避免不必要的抗生素治疗和限制住院治疗中的重要性。TPPs通常会自发消退,但感染或出血等并发症可能需要干预。早期识别和量身定制的管理对于优化结果至关重要。
{"title":"[Traumatic pulmonary pseudocyst].","authors":"Arnaud Lempereur, Michèle Yerna, Ali Deeba","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Traumatic pulmonary pseudocysts (TPPs) are rare but clinically relevant complications of thoracic trauma, often misdiagnosed due to their non-specific presentation and resemblance to other cavitary pulmonary lesions. We report the case of a 26-year-old male presenting with delayed symptoms following a fall, ultimately diagnosed with multiple TPPs via thoracic CT scan. The patient experienced a favourable evolution with conservative management, including aerosolized tranexamic acid for minor hemoptysis. This case highlights the importance of thorough clinical history-taking and imaging in establishing the diagnosis, avoiding unnecessary antibiotic therapy, and limiting hospitalization. TPPs generally resolve spontaneously, but complications such as infection or hemorrhage may require intervention. Early recognition and tailored management are essential to optimize outcomes.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"563-566"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Biomarkers for an early detection of patients at risk of renal or cardiovascular disease]. [早期发现有肾脏或心血管疾病风险的患者的生物标志物]。
Pub Date : 2025-09-01
André Scheen, Pierre Delanaye, François Jouret, Patrizio Lancellotti, Étienne Cavalier

Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD. The use of these biomarkers remains too low in clinical practice whereas medications are now available (or will come very soon as for lipoprotein (a) - which allow minimizing the risk and improving the overall prognosis. Notably, it is the case with sodium-glucose cotransporter type 2 inhibitors (gliflozins) as far as CKD and HF are concerned.

慢性肾脏疾病(CKD)、心力衰竭(HF)和动脉粥样硬化性心血管疾病(ASCVD)是一种长期隐匿的疾病,因此在临床实践中很大程度上未被诊断。生物标志物的使用可能有助于在早期阶段发现已经患有这些疾病的人或在不久的将来患这些疾病的风险增加的人。本文的目的是讨论蛋白尿、利钠肽(BNP/proBNP)和高敏感性肌钙蛋白以及脂蛋白(a)检测的地位,以帮助有CKD、HF或ASCVD风险的个体进行诊断和预后评估。在临床实践中,这些生物标记物的使用仍然太少,而现在已有(或很快就会有)针对脂蛋白(a)的药物,可以将风险降到最低,并改善总体预后。值得注意的是,就CKD和HF而言,钠-葡萄糖共转运蛋白2型抑制剂(格列净)就是这种情况。
{"title":"[Biomarkers for an early detection of patients at risk of renal or cardiovascular disease].","authors":"André Scheen, Pierre Delanaye, François Jouret, Patrizio Lancellotti, Étienne Cavalier","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD. The use of these biomarkers remains too low in clinical practice whereas medications are now available (or will come very soon as for lipoprotein (a) - which allow minimizing the risk and improving the overall prognosis. Notably, it is the case with sodium-glucose cotransporter type 2 inhibitors (gliflozins) as far as CKD and HF are concerned.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"612-617"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Ileal diverticulitis, a rare etiology of digestive bleeding]. [回肠憩室炎,消化道出血的罕见病因]。
Pub Date : 2025-09-01
Sonia Mendil, Maud Van Buggenhout, Emmanuel Decker, Raphaelle Massa, Flavien Grandjean

Small bowel diverticulosis is a rare and predominantly asymptomatic condition that mainly affects elderly individuals. Hemorrhagic complications, though rare, can be life-threatening. In cases of suspected bleeding, CT angiography is recommended to diagnose, localize, and assess the severity of the hemorrhage. Therapeutic management varies, ranging from conservative treatment to surgical intervention, with embolization in interventional radiology as an alternative option.

小肠憩室病是一种罕见且主要无症状的疾病,主要影响老年人。出血性并发症虽然罕见,但可能危及生命。在怀疑出血的病例中,建议使用CT血管造影来诊断、定位和评估出血的严重程度。治疗方法各不相同,从保守治疗到手术干预,介入放射学中的栓塞治疗是另一种选择。
{"title":"[Ileal diverticulitis, a rare etiology of digestive bleeding].","authors":"Sonia Mendil, Maud Van Buggenhout, Emmanuel Decker, Raphaelle Massa, Flavien Grandjean","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Small bowel diverticulosis is a rare and predominantly asymptomatic condition that mainly affects elderly individuals. Hemorrhagic complications, though rare, can be life-threatening. In cases of suspected bleeding, CT angiography is recommended to diagnose, localize, and assess the severity of the hemorrhage. Therapeutic management varies, ranging from conservative treatment to surgical intervention, with embolization in interventional radiology as an alternative option.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"553-555"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[One-year clinical results of the Multidisciplinary Consultation at the Emphysema Clinic of CHU Liege]. 【朱列日肺气肿门诊多学科会诊1年临床结果分析】。
Pub Date : 2025-09-01
Romain Alfieri, Bernard Duysinx, Renaud Louis, Vincent Heinen

Severe emphysema impairs lung function and quality of life in patients with Chronic Obstructive Pulmonary Disease (COPD). Despite optimized medical treatment and rehabilitation, some patients require lung volume reduction interventions (endoscopic or surgical). This study evaluates one-year outcomes of patients managed at the Emphysema Clinic of CHU Liège. This retrospective observational and longitudinal single-center study included 65 patients discussed in multidisciplinary meetings between 2021 and 2023. Patients were divided into two groups: treated (n = 24) with bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV), lung volume reduction surgery (LVRS), or referred for lung transplantation (LTx); and non-treated (n = 41). Clinical and functional parameters were compared at baseline (T0) and after one year (T1). At one year, treated patients showed a significant improvement in forced expiratory volume in 1 second (FEV1 : +8.19 %, p = 0.0051), six-minute walk test distance (+54.6 m, p = 0.018), and COPD Assesment Test (CAT score : -5.3 points, p = 0.0017). Advanced interventions for emphysema improve respiratory function, walking distance and quality of life in selected patients based on strict criteria and multidisciplinary consultation.

严重肺气肿损害慢性阻塞性肺疾病(COPD)患者的肺功能和生活质量。尽管优化了药物治疗和康复,但一些患者需要肺减容干预(内窥镜或手术)。本研究评估了在CHU医院肺气肿诊所治疗的患者一年的预后。这项回顾性观察和纵向单中心研究纳入了2021年至2023年多学科会议上讨论的65例患者。患者被分为两组:支气管镜下使用支气管内瓣膜(EBV)进行肺减容(BLVR)治疗(n = 24),肺减容手术(LVRS)或转介肺移植(LTx);和未治疗组(n = 41)。在基线(T0)和一年后(T1)比较临床和功能参数。治疗一年后,患者1秒用力呼气量(FEV1: + 8.19%, p = 0.0051)、6分钟步行测试距离(+54.6 m, p = 0.018)和COPD评估测试(CAT评分:-5.3分,p = 0.0017)均有显著改善。根据严格的标准和多学科咨询,对肺气肿进行先进的干预可以改善选定患者的呼吸功能、步行距离和生活质量。
{"title":"[One-year clinical results of the Multidisciplinary Consultation at the Emphysema Clinic of CHU Liege].","authors":"Romain Alfieri, Bernard Duysinx, Renaud Louis, Vincent Heinen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Severe emphysema impairs lung function and quality of life in patients with Chronic Obstructive Pulmonary Disease (COPD). Despite optimized medical treatment and rehabilitation, some patients require lung volume reduction interventions (endoscopic or surgical). This study evaluates one-year outcomes of patients managed at the Emphysema Clinic of CHU Liège. This retrospective observational and longitudinal single-center study included 65 patients discussed in multidisciplinary meetings between 2021 and 2023. Patients were divided into two groups: treated (n = 24) with bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV), lung volume reduction surgery (LVRS), or referred for lung transplantation (LTx); and non-treated (n = 41). Clinical and functional parameters were compared at baseline (T0) and after one year (T1). At one year, treated patients showed a significant improvement in forced expiratory volume in 1 second (FEV1 : +8.19 %, p = 0.0051), six-minute walk test distance (+54.6 m, p = 0.018), and COPD Assesment Test (CAT score : -5.3 points, p = 0.0017). Advanced interventions for emphysema improve respiratory function, walking distance and quality of life in selected patients based on strict criteria and multidisciplinary consultation.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"567-575"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revue medicale de Liege
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1